Literature DB >> 20155256

In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population.

Natasa Djordjevic1, Juan Antonio Carrillo, Guillermo Gervasini, Slobodan Jankovic, Eleni Aklillu.   

Abstract

PURPOSE: The main aim of the study was to investigate the distribution of cytochrome P450 2A6 (CYP2A6) and xanthine oxidase (XO) enzyme activities in the Serbian population. Secondly, we tested the influence of genetics (CYP2A6 polymorphism), sex, and cigarette smoking on both enzymes.
METHODS: One hundred forty healthy Serbian volunteers were genotyped for common CYP2A6 alleles. In 100 of them, CYP2A6 and XO activities were determined by the urinary 17U/17X and 1U/(1U + 1X) ratios, respectively, after oral administration of 100 mg caffeine as a probe.
RESULTS: A 21-fold variation in the 17U/17X ratio was observed (range: 0.49-10.28, mean = 1.65, 95% CI: 1.49-1.83). The urinary 1U/(1U + 1X) ratios displayed four-fold variation, ranging from 0.17 to 0.71 (mean = 0.43, 95% CI: 0.41-0.45). CYP2A6 alleles *1A, *1B1, *9, *4 and *1B1x2 were found with frequencies of 0.579, 0.307, 0.082, 0.029, and 0.004 respectively. CYP2A6*5 was not detected. CYP2A6 genotype influenced interindividual variability in CYP2A6 enzyme activity (P = 0.04). Cigarette smoking inhibited CYP2A6 enzyme activity (P = 0.02), but had no effect on activity of XO (P = 0.16).There was no significant difference between men and women in terms of CYP2A6 or XO activity.
CONCLUSIONS: Serbs displayed interindividual variations in CYP2A6 activity. CYP2A6 genotype and cigarette smoking, but not sex, influenced CYP2A6 enzyme activity. Unimodal distribution of XO enzyme activity in Serbs implies the absence of subjects with low enzyme activity in this population. XO activity is not influenced by sex or cigarette smoking.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20155256     DOI: 10.1007/s00228-010-0785-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  43 in total

1.  Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort.

Authors:  N Gambier; A-M Batt; B Marie; M Pfister; G Siest; S Visvikis-Siest
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

2.  A novel duplication type of CYP2A6 gene in African-American population.

Authors:  Tatsuki Fukami; Miki Nakajima; Hiroyuki Yamanaka; Yasunari Fukushima; Howard L McLeod; Tsuyoshi Yokoi
Journal:  Drug Metab Dispos       Date:  2007-01-31       Impact factor: 3.922

3.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

4.  In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.

Authors:  E Begas; E Kouvaras; A Tsakalof; S Papakosta; E K Asprodini
Journal:  Biomed Chromatogr       Date:  2007-02       Impact factor: 1.902

5.  Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism.

Authors:  W G Chung; J H Kang; C S Park; M H Cho; Y N Cha
Journal:  Clin Pharmacol Ther       Date:  2000-03       Impact factor: 6.875

6.  Female sex and oral contraceptive use accelerate nicotine metabolism.

Authors:  Neal L Benowitz; Christina N Lessov-Schlaggar; Gary E Swan; Peyton Jacob
Journal:  Clin Pharmacol Ther       Date:  2006-05       Impact factor: 6.875

Review 7.  Structure and function of xanthine oxidoreductase: where are we now?

Authors:  Roger Harrison
Journal:  Free Radic Biol Med       Date:  2002-09-15       Impact factor: 7.376

8.  Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies.

Authors:  D M Grant; M E Campbell; B K Tang; W Kalow
Journal:  Biochem Pharmacol       Date:  1987-04-15       Impact factor: 5.858

9.  Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.

Authors:  M V Relling; J S Lin; G D Ayers; W E Evans
Journal:  Clin Pharmacol Ther       Date:  1992-12       Impact factor: 6.875

10.  Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.

Authors:  B B Rasmussen; K Brøsen
Journal:  Ther Drug Monit       Date:  1996-06       Impact factor: 3.681

View more
  8 in total

1.  PharmGKB summary: caffeine pathway.

Authors:  Caroline F Thorn; Eleni Aklillu; Ellen M McDonagh; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-05       Impact factor: 2.089

2.  Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism.

Authors:  Natasa Djordjevic; Roza Ghotbi; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

3.  Distribution of xanthine oxidase activity in a Nigerian population.

Authors:  Ayorinde Adehin; Oluseye Oladotun Bolaji
Journal:  Eur J Clin Pharmacol       Date:  2015-05-05       Impact factor: 2.953

4.  Association between the CYP1A2 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Wen-Xia Sun; Ying-Hua Chen; Zhi-Zhong Liu; Jian-Jun Xie; Wei Wang; Ya-Ping Du; Yu Chen; Xu-Liang Shen; Xiao-Feng He; Li-Xia Wu; Wu Wei; Lin Zhang
Journal:  Mol Genet Genomics       Date:  2014-12-04       Impact factor: 3.291

5.  High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.

Authors:  Eleni Aklillu; Natasa Djordjevic; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  OMICS       Date:  2013-12-31

Review 6.  PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

Authors:  Ellen M McDonagh; Catherine Wassenaar; Sean P David; Rachel F Tyndale; Russ B Altman; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-09       Impact factor: 2.089

Review 7.  Variation in CYP2A6 Activity and Personalized Medicine.

Authors:  Julie-Anne Tanner; Rachel F Tyndale
Journal:  J Pers Med       Date:  2017-12-01

Review 8.  Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.

Authors:  Luis A López-Flores; Gloria Pérez-Rubio; Ramcés Falfán-Valencia
Journal:  EXCLI J       Date:  2017-03-06       Impact factor: 4.068

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.